When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) .Vertex currently has an average brokerage recommendation (ABR) o ...

Vertex just laid claim to an asset that might be very valuable.Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (VRTX -0.92%) announced it would purchase Alpine Immune Sciences (ALPN -0.05%) for $4.9 billion in cash in a deal that's set to close before the end of this quarter. The prized asset that Vertex will gain as part of this purchase is ALPN-303, a potential autoimmune treatment that's in phase 2 clinical trials.But there's a lot more to the deal's potential value ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?Vertex Pharmaceuticals (VRTX -1.71%) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now hitting the $100 billion mark, has it become too expensive of an investment? Is it time for investors to consider other stocks instead, or can Vertex still be a good buy right now?Let's dive in and take a look.Why investor ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $397.58, marking a -1.71% move from the previous day. This change lagged the S&P 500's 0.95% loss on the day. At the same time, the Dow lost 1.09%, and the tech-heavy Nasdaq lost 0.84%.Prior to today's trading, shares of the drugmaker had lost 1.93% over the past month. This has was narrower than the Medical sector's loss of 3.76% and lagged the S&P 500's gain of 1.78% in that time.Market participants will be closely following the financ ...

This innovative machine rolls on.Biotech giant Vertex Pharmaceuticals (VRTX -0.82%) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive phase 3 results for exciting candidates.The drugmaker isn't stopping. Vertex is moving forward with another investigational medicine that could become a big deal somewhere down the road. Let's find out what it is and what it could mean for investors.Straight out of the playbookFirst, l ...

Vertex Pharmaceuticals (VRTX) initiated the late-stage portion of the phase II/III AMPLITUDE study evaluating inaxaplin (VX-147) in APOL1-mediated kidney disease (AMKD), a genetic disorder affecting kidney function.This phase III portion will evaluate a 45 mg oral dose of Vertex’s drug, on top of standard of care, in AMKD patients, compared with placebo. Management also expanded the study to include adolescents aged 10 and older with AMKD. Previously, the AMPLITUDE study only enrolled adults with the diseas ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $420.48, with a +0.59% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.2%. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%.Prior to today's trading, shares of the drugmaker had lost 3.41% over the past month. This has lagged the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.The investment community will be c ...

Biotech giant Vertex Pharmaceuticals (VRTX 0.17%) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while displaying its incredible innovative abilities. Thankfully, it's not too late to invest in Vertex even with the market-beating returns it has provided in recent years.The company's underlying business remains as strong as ever -- strong enough that the stock is an excellent "forever" pick. Let's find out more.VRTX ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has cleared its investigational new drug application to begin clinical development of its pipeline candidate, VX-407, for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Vertex plans to begin a phase I study on VX-407 in ADPKD later this month.VX-407 is a first-in-class small molecule corrector that targets the underlying cause of this common inherited kidney disease, which leads to growth of several kidney-enlarging cy ...